Medicare drug coverage

Copaxone: 2027 Medicare Part D coverage

1,124 of 5,495 Part D plans (20%) list Copaxone on their 2027 formulary, up 4 points from 2026. 100% of those require prior authorization, step therapy, or a quantity limit.

License. US government work, Public Domain Mark 1.0.

2027 compared with 2026

Copaxone is number 160 by total Medicare Part D spending in 2024 ($257 million). Plans that list it most often put it on tier 5. Counts use 3 RxNorm products for this name.

Copaxone Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it922 (17%)1,124 (20%)+4 points
Prior authorization (of plans that list it)903 (98%)1,118 (99%)+2 points
Step therapy (of plans that list it)6 (1%)6 (1%)no change
Quantity limit (of plans that list it)848 (92%)1,124 (100%)+8 points
Any of the three (of plans that list it)922 (100%)1,124 (100%)no change
Not listed or restricted (of all plans)5,518 (100%)5,495 (100%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Formulary tier

Copaxone formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 143 (5%)25 (2%)
Tier 43 (0%)0 (0%)
Tier 5876 (95%)1,099 (98%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan ids are in both files. 54 of them (1%) added prior authorization, step therapy, or a quantity limit for Copaxone, and 53 stopped listing it.

Copaxone: plans in both 2026 and 2027
Plan by planPlans
Same plan id in both years4,380
Listed it in 2026, not in 202753 (1%)
Listed it in 2027, not in 20267 (0%)
Moved it to a higher tier4 (0%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit54 (1%)
Added at least one of the three54 (1%)
Removed at least one of the three0 (0%)
Plan ids new in 20271,115
2026 plan ids not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Copaxone off the formulary or list it with prior authorization, step therapy, or a quantity limit. Hawaii ranks first at 100%, with 48% of its plans using prior authorization or step therapy; Wyoming ranks last at 100%. Ties break on the prior authorization or step therapy share.

States from most to least restrictive for Copaxone, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Hawaii50100%48%no change
2Alabama115100%35%no change
3Maryland49100%35%no change
4Pennsylvania324100%34%no change
5Oregon92100%32%no change
6Arizona148100%31%no change
7Tennessee157100%29%no change
8New York215100%28%no change
9Connecticut54100%26%no change
10Illinois133100%24%no change
11New Hampshire25100%24%no change
12Indiana140100%23%no change
13Washington114100%23%no change
14Arkansas86100%21%no change
15Ohio173100%21%no change
16North Carolina177100%20%no change
17Colorado106100%20%no change
18Nebraska51100%20%no change
19California397100%19%no change
20Florida549100%19%no change
21Mississippi105100%19%no change
22Delaware43100%19%no change
23Louisiana126100%18%no change
24Missouri171100%18%no change
25New Mexico68100%18%no change
26Iowa64100%17%no change
27Texas412100%16%no change
28Maine52100%15%no change
29Massachusetts92100%15%no change
30Utah53100%15%no change
31Oklahoma81100%15%no change
32Michigan183100%15%no change
33Vermont14100%14%no change
34Rhode Island29100%14%no change
35Kansas84100%13%no change
36Virginia145100%12%no change
37West Virginia70100%11%no change
38South Carolina91100%11%no change
39Georgia151100%11%no change
40Kentucky123100%11%no change
41New Jersey74100%8%no change
42Idaho45100%7%no change
43District of Columbia21100%5%no change
44Wisconsin97100%4%no change
45Nevada100100%4%no change
46Minnesota63100%2%no change
47Alaska9100%0%no change
48Montana27100%0%no change
49North Dakota26100%0%no change
50South Dakota30100%0%no change
51Wyoming13100%0%no change

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Copaxone off or restrict it.

Copaxone coverage by parent organization, 2027
Parent organization2027 plans ↓List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
Humana Inc.8840%none list it100%no change0
UnitedHealth Group, Inc.8500%none list it100%no change0
Devoted Health, Inc.728100%100%100%no change0
CVS Health Corporation6330%none list it100%no change0
Elevance Health, Inc.2940%none list it100%no change0
Centene Corporation2680%none list it100%no change0
Health Care Service Corporation2310%none list it100%no change0
Kaiser Foundation Health Plan, Inc.1120%none list it100%no change0
Highmark Health9893%100%100%no change0
SCAN Group85100%100%100%no change54
Alignment Healthcare USA, LLC770%none list it100%no change0
Guidewell Mutual Holding Corporation5531%100%100%no change0
Blue Cross Blue Shield of Michigan Mutual Ins. Co.430%none list it100%no change0
Molina Healthcare, Inc.43100%100%100%no change0
Corewell Health400%none list it100%no change0
Zing Health Consolidator, Inc36100%100%100%no change0
CAPITAL BLUE CROSS350%none list it100%no change0
Medica Holding Company310%none list it100%no change0
UPMC Health System300%none list it100%no change0
Universal Health Services, Inc.290%none list it100%no change0
MHH Healthcare, L.P.260%none list it100%no change0
Independence Health Group, Inc.2524%100%100%no change0
Point32Health, Inc.230%none list it100%no change0
BlueCross BlueShield of Tennessee220%none list it100%no change0
California Physicians' Service220%none list it100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Run it in Rivvi

Which 2027 plans near you dropped or restricted Copaxone?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan, before open enrollment.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing